Andere Sprachen Redwood Pharma AB

Aktien

A403LN

SE0021512134

REDW

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:59 03.05.2024			% 5 Tage	% 1. Jan.
0,806 ^SEK	-0,25 %		-21,75 %	-82,85 %

23.04.	Redwood Pharma AB meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
15.02.	Redwood Pharma AB meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	23.04.
Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle	28.02.
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15.02.
Redwood Pharma's CEO Martin Vidaeus in year-end interview	20.12.
Redwood Pharma to participate in the JP Morgan Healthcare Conference	19.12.
Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)	30.11.
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23.11.
Redwood Pharma to participate in the NLS Days partner conference in Copenhagen	22.11.
Redwood Pharma to participate in the BIO-Europe partnering conference in Munich	19.10.23
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07.08.23
Redwood Pharma presents positive results from a clinical study with RP501 against dry eye	31.05.23
Redwood Pharma AB Presents Positive Results from Clinical Study with RP501 Against Dry Eye	31.05.23
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09.05.23
Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye	17.03.23
Redwood Pharma AB Completes Recruitment for Clinical Trial with RP501 for Dry Eye	17.03.23
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	15.02.23
Redwood Pharma to Scale-up Production for Upcoming Commercialization of Eye Dry Treatment	24.01.23
Redwood Pharma takes important steps towards the commercial production of its dry eye product	24.01.23
Redwood Pharma AB Completes Further Preparations for the Scale-Up of Production of the Company's Medical Technology Product RP501	24.01.23
Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501	15.12.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Redwood Pharma AB

Aktien

A403LN

SE0021512134

REDW

Andere Sprachen

Filter